El continuo de la EPOC y riesgo cardiovascularuna hipótesis global de la enfermedad
- 1 Servicio de Medicina Interna y Medicina de Familia, CAP-Marín EOXI Pontevedra-Salnés
- 2 Servicio de Neumología, CHUP Pontevedra-Salnés
ISSN: 0214-9168, 1578-1879
Year of publication: 2015
Volume: 27
Issue: 3
Pages: 144-147
Type: Article
More publications in: Clínica e investigación en arteriosclerosis
Abstract
Chronic obstructive pulmonary disease (COPD) is a serious public health problem in our country. COPD is a treatable and preventable disease which is underdiagnosed. The EPISCAN study revealed a prevalence of 10.2% in Spain between individuals of 40-80 years, with 73% underdiagnosis. In Primary Care occupies 8.5% of all queries with a high economic impact. These patients exhibit some degree of systemic inflammation characterized by increased plasma levels of some inflammatory mediators such as IL-1, IL-6, IL-8, CRP and TNF, which are also related to endothelial disorders and arteriosclerosis. In the continuum of COPD, comorbidities most frequently appear are: ischemic heart disease, heart failure, stroke, hypertension, type 2 diabetes mellitus, renal failure, osteoporosis, myopathy, anxiety, depression, cognitive impairment, malnutrition, anemia and lung cancer.